Literature DB >> 8149659

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions.

P Ettehadi1, M W Greaves, D Wallach, D Aderka, R D Camp.   

Abstract

Lesions of the common inflammatory skin disease psoriasis are characterized by epidermal hyperproliferation, leucocyte adhesion molecule expression and leucocyte infiltration. The local release of proinflammatory cytokines, such as TNF-alpha, may play an important role in the induction of these events. We have, therefore, analysed aqueous extracts of lesional and uninvolved (clinically normal) stratum corneum for the presence of TNF-alpha immunoreactivity and biological activity. TNF-alpha immunoreactivity and bioactivity were consistently higher in lesional compared with uninvolved samples. By using an anti-TNF-alpha neutralizing antibody it was demonstrated that the biological activity measured was due to the presence of TNF-alpha alone. Concentrations of soluble TNF receptors (p55 and p75) were also higher in lesional stratum corneum extracts, with the p55 form predominating. The plasma of psoriatic patients was also found to contain elevated concentrations of soluble p55 compared with normal controls. These results confirm the presence of immunoreactive TNF-alpha and, for the first time, conclusively demonstrate TNF-alpha biological activity and quantifiable concentrations of soluble TNF receptors (p55 and p75) in lesional psoriatic samples. TNF-alpha recovery from stratum corneum probably reflects synthesis in deeper, viable layers, where it is likely to exert its biological effects. Local and systemic release of soluble TNF receptors, in particular p55, may serve to regulate the effects of TNF-alpha in psoriasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149659      PMCID: PMC1534536          DOI: 10.1111/j.1365-2249.1994.tb06244.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  The active form of tumor necrosis factor is a trimer.

Authors:  R A Smith; C Baglioni
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

2.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

Authors:  T Espevik; J Nissen-Meyer
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303

3.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

Authors:  M Brockhaus; H J Schoenfeld; E J Schlaeger; W Hunziker; W Lesslauer; H Loetscher
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis.

Authors:  H Takematsu; H Ohta; H Tagami
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

5.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

Authors:  H Engelmann; D Aderka; M Rubinstein; D Rotman; D Wallach
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

6.  Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain.

Authors:  U Gullberg; M Lantz; L Lindvall; I Olsson; A Himmler
Journal:  Eur J Cell Biol       Date:  1992-08       Impact factor: 4.492

7.  Structure of tumour necrosis factor.

Authors:  E Y Jones; D I Stuart; N P Walker
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

8.  Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor.

Authors:  C E Griffiths; J J Voorhees; B J Nickoloff
Journal:  J Am Acad Dermatol       Date:  1989-04       Impact factor: 11.527

9.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

10.  Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF).

Authors:  A Meager; S Parti; H Leung; E Peil; B Mahon
Journal:  Hybridoma       Date:  1987-06
View more
  74 in total

1.  Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo.

Authors:  R E Eliaz; D Wallach; J Kost
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 3.  MicroRNAs in skin and wound healing.

Authors:  Jaideep Banerjee; Yuk Cheung Chan; Chandan K Sen
Journal:  Physiol Genomics       Date:  2010-10-19       Impact factor: 3.107

4.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors:  A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

5.  Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy.

Authors:  Grigorios T Sakellariou; Periklis Vounotrypidis; Charalampos Berberidis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 2.980

6.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

Authors:  A W R van Kuijk; P Reinders-Blankert; T J M Smeets; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

7.  Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.

Authors:  J Gratacós; E Casado; J Real; J C Torre-Alonso
Journal:  Ann Rheum Dis       Date:  2006-12-19       Impact factor: 19.103

8.  Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.

Authors:  Lynda Grine; Lien Dejager; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

9.  Development and validation of human psoriatic skin equivalents.

Authors:  Geuranne Tjabringa; Mieke Bergers; Desiree van Rens; Roelie de Boer; Evert Lamme; Joost Schalkwijk
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

10.  Cytokine expression in psoriatic skin lesions during PUVA therapy.

Authors:  A K Olaniran; B S Baker; D G Paige; J J Garioch; A V Powles; L Fry
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.